Anticoagulation Duration in Intermediate-High Risk Pulmonary Thromboembolism

Initial Treatment: First 3 Months

All patients with pulmonary thromboembolism (PTE) require a minimum of 3 months of therapeutic anticoagulation to prevent thrombus extension and early recurrence, according to the American College of Chest Physicians 1, 2, 3
Initial treatment should be started with low molecular weight heparin (LMWH) or fondaparinux, followed by vitamin K antagonists (VKAs) with a target INR of 2.5 (range 2.0-3.0), as recommended by the European Society of Cardiology 4, 1

For patients with provoked PTE due to surgery, anticoagulation can be stopped at 3 months (annual recurrence risk <1%), based on guidelines from the American College of Chest Physicians 1, 2, 5
For patients with unprovoked PTE, the risk of recurrence is higher (>5% per year after stopping anticoagulation), and extended anticoagulation should be considered, according to the Journal of Thrombosis and Haemostasis 3, 5

Patients with intermediate-high risk PTE do not require routine thrombolysis but should be closely monitored during the acute phase, as recommended by the European Society of Cardiology 4
The duration of anticoagulation is based on whether the event was provoked or unprovoked, not on the initial risk classification, according to the American College of Chest Physicians 1, 2

Annual reevaluation is mandatory to assess bleeding risk factors, medication adherence, patient preference, liver and kidney function, and drug tolerance, as recommended by the European Society of Cardiology 4, 6, 7
Options for extended anticoagulation therapy include VKAs with INR 2.0-3.0, as recommended by the American College of Chest Physicians 1, 2

Do not automatically stop anticoagulation at 6 or 12 months, as there is no additional benefit compared to 3 months if anticoagulation is to be stopped, according to the American College of Chest Physicians 1, 3, 2
Do not treat all events as equal, as the distinction between provoked and unprovoked PTE is the strongest predictor of recurrence, according to the Journal of Thrombosis and Haemostasis 3, 5

For PTE associated with active cancer, extended anticoagulation is strongly recommended, regardless of bleeding risk (Grade 1B for low/moderate risk, Grade 2B for high risk), according to the American College of Chest Physicians 1, 2
For a second unprovoked PTE event, extended anticoagulation is strongly recommended (Grade 1B for low risk, Grade 2B for moderate risk), according to the American College of Chest Physicians 1, 2, 6